- Home
- ELVN
as 07-04-2025 11:33am EST
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.2B | IPO Year: | 2020 |
| Target Price: | $41.20 | AVG Volume (30 days): | 747.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.30 - $30.03 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Jun 9 '25 | Sell | $20.74 | 6,667 | $135,574.05 | 303,369 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jun 3 '25 | Sell | $20.03 | 7,500 | $150,219.75 | 977,688 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | May 27 '25 | Sell | $16.18 | 3,250 | $52,593.45 | 23,000 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | May 19 '25 | Sell | $16.31 | 5,000 | $81,533.50 | 977,688 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | May 19 '25 | Sell | $16.49 | 5,000 | $82,453.00 | 972,892 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | May 7 '25 | Sell | $19.19 | 6,667 | $122,578.86 | 303,369 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | May 1 '25 | Sell | $20.04 | 7,500 | $150,390.64 | 977,688 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | May 1 '25 | Sell | $20.04 | 7,500 | $150,415.36 | 972,892 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Apr 28 '25 | Sell | $18.90 | 3,250 | $60,737.55 | 23,000 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Apr 21 '25 | Sell | $16.37 | 5,000 | $80,365.82 | 977,688 |
Latest Enliven Therapeutics Inc. News
ELVN Breaking Stock News: Dive into ELVN Ticker-Specific Updates for Smart Investing
Insider Monkey
19 days ago
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data
MT Newswires
20 days ago
Enliven Therapeutics Closes Public Offering
PR Newswire
20 days ago
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
MT Newswires
23 days ago
Sector Update: Health Care Stocks Slide Late Afternoon
MT Newswires
23 days ago
Top Midday Gainers
MT Newswires
23 days ago
Enliven Therapeutics Prices $200 Million Public Offering of Common Stock, Pre-Funded Warrants
PR Newswire
23 days ago
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
MT Newswires
24 days ago
Enliven's Chronic Myeloid Leukemia Candidate Achieves MMR Rate in Phase 1 Trial
Compare ELVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.